Answer
The most frequently reported adverse reactions to umeclidinium bromide in patients with COPD are nasopharyngitis (6%) and upper respiratory tract infection (5%).
Sources for this answer
- Incruse Ellipta 55 micrograms inhalation powder, pre-dispensedGlaxoSmithKline UK · emc · SmPC §4.8 Undesirable effects · Version 18Document updated
Sources checked